Unknown

Dataset Information

0

TET2 Inhibits PD-L1 Gene Expression in Breast Cancer Cells through Histone Deacetylation.


ABSTRACT: Activation of PD-1/PD-L1 checkpoint is a critical step for the immune evasion of malignant tumors including breast cancer. However, the epigenetic mechanism underlying the aberrant expression of PD-L1 in breast cancer cells remains poorly understood. To investigate the role of TET2 in the regulation of PD-L1 gene expression, quantitative reverse transcription PCR (RT-qPCR), Western blotting, chromatin immunoprecipitation (ChIP) assay and MeDIP/hMeDIP-qPCR were performed on MCF7 and MDA-MB-231 human breast cancer cells. Here, we reported that TET2 depletion upregulated PD-L1 gene expression in MCF7 cells. Conversely, ectopic expression of TET2 inhibited PD-L1 gene expression in MDA-MB-231 cells. Mechanistically, TET2 protein recruits histone deacetylases (HDACs) to PD-L1 gene promoter and orchestrates a repressive chromatin structure to suppress PD-L1 gene transcription, which is likely independent of DNA demethylation. Consistently, treatment with HDAC inhibitors upregulated PD-L1 gene expression in wild-type (WT) but not TET2 KO MCF7 cells. Furthermore, analysis of the CCLE and TCGA data showed a negative correlation between TET2 and PD-L1 expression in breast cancer. Taken together, our results identify a new epigenetic regulatory mechanism of PD-L1 gene transcription, linking the catalytic activity-independent role of TET2 to the anti-tumor immunity in breast cancer.

PROVIDER: S-EPMC8125390 | BioStudies |

REPOSITORIES: biostudies

Similar Datasets

| S-EPMC8794171 | BioStudies
| S-EPMC5283623 | BioStudies
| S-EPMC5855785 | BioStudies
| S-EPMC3925108 | BioStudies
| S-EPMC5889210 | BioStudies
| S-EPMC6721435 | BioStudies
| S-EPMC3981956 | BioStudies
| S-EPMC7004876 | BioStudies
2016-01-01 | S-EPMC5342531 | BioStudies
| S-EPMC8158060 | BioStudies